Steven Deitelzweig, MD
- Sr Physician-Service Line Leader, Southshore Region
- 1514 Jefferson Hwy, New Orleans, LA, 70121
For additional information or to make an appointment, click here.
Overview
Overview
- Dr. Deitelzweig earned his medical degree from State University of New York at Stony Brook and completed his internship and residency at Cornell University Medical College and Northshore University Hospital. He completed fellowships in hepatology and vascular medicine at Ochsner and holds an Executive Masters in Health Care Administration from the University of New Orleans. He is a fellow of the American College of Physicians and has been honored as one of the 'Best Doctors in America' in 2006. Dr. Deitelzweig is board certified in Internal Medicine and Hospice and Palliative Medicine. He is a Clinical Associate Professor at Tulane University School of Medicine. Dr. Deitelzweig serves as the Vice President of Medical Affairs for the Ochsner Health and Chairman of the Dept of Hospital Medicine. He has been on staff at Ochsner since 1993.
Publications
Selected publications
-
2023Payer formulary tier increases of apixaban: how patients respond and potential implications. Current Medical Research and Opinion.
-
2023Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study. European Journal of Internal Medicine. 108:37-42.
-
2022Payer formulary exclusions of apixaban: how patients respond and potential implications. Current Medical Research and Opinion.
-
2022Impact of apixaban treatment discontinuation on the risk of hospitalization among patients with nonvalvular atrial fibrillation and COVID-19. Current Medical Research and Opinion.
-
2022
-
2022Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. Journal of Thrombosis and Thrombolysis.
-
2022Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study. Journal of Thrombosis and Thrombolysis.
-
2022Effectiveness and Safety of Apixaban Versus Warfarin in Obese Patients with Nonvalvular Atrial Fibrillation Enrolled in Medicare and Veteran Affairs. American Journal of Cardiology. 163:43-49.
-
2021Cost Effectiveness of Andexanet Alfa for Major Gastrointestinal Bleeding Associated With Factor Xa Inhibitors. American Journal of Gastroenterology. 116:S298-S298.
-
2021
-
2021Time at home among nonvalvular atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants versus warfarin. European Heart Journal. 42:573-573.
-
2021
-
2021Response to a letter by Jolobe: ARISTOPHANES subgroup analysis of frail and older patients with NVAF receiving low doses of novel oral anticoagulants. Journal of Internal Medicine. 290:221-222.
-
2021Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity. Advances in Therapy. 38:3166-3184.
-
2020Major bleed costs of atrial fibrillation patients treated with factor Xa inhibitor anticoagulants. JOURNAL OF MEDICAL ECONOMICS.
-
2020Utilization of anticoagulants and predictors of treatment among hospitalized patients with atrial fibrillation in the USA. JOURNAL OF MEDICAL ECONOMICS.
-
2020The Burden of Major Bleeds among Atrial Fibrillation Patients Treated With Direct-acting Oral Anticoagulants in the United States. Annals of Emergency Medicine. 76:S5-S5.
-
2020Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom. Expert Review of Pharmacoeconomics and Outcomes Research. 20:259-267.
-
2020Comparison of readmissions among hospitalized nonvalvular atrial fibrillation patients treated with oral anticoagulants in the United States. Journal of Drug Assessment. 9:87-96.
-
2020Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study. Journal of Clinical Medicine. 9.
-
2020Effectiveness and Safety of Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus. Mayo Clinic Proceedings. 95:929-943.
-
2020Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. American Journal of Medicine. 133:1-27.
-
2020Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. Journal of Internal Medicine.
-
2020Reduce the Likelihood of Patient Harm Associated with the Use of Anticoagulant Therapy: Commentary from the Anticoagulation Forum on the Updated Joint Commission NPSG.03.05.01 Elements of Performance. Joint Commission Journal on Quality and Patient Safety. 46:173-180.
-
2020Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. Journal of Thrombosis and Thrombolysis. 50:72-81.
-
2020Utilization of anticoagulants and predictors of treatment among hospitalized patients with atrial fibrillation in the USA. Journal of Medical Economics (JME).
-
2019Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. Journal of the American Geriatrics Society. 67:1662-1671.
-
2019Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US. Journal of Medical Economics (JME). 22:1119-1125.
-
2019REHOSPITALIZATIONS FOR VENOUS THROMBOEMBOLISM AND ASSOCIATED COSTS AMONG PATIENTS WITH HEART FAILURE. Critical Care Medicine. 47.
-
2019Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review. Expert Review of Pharmacoeconomics and Outcomes Research. 19:243-244.
-
2019The burden of hospital readmissions for venous thromboembolism among acute medically ill patients in the US. Journal of Thrombosis and Thrombolysis. 47:622-622.
-
2018All-Cause, Stroke/Systemic Embolism-, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants. Clinical and Applied Thrombosis/Hemostasis. 24:602-611.
-
2018Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. Current Medical Research and Opinion. 34:487-498.
-
2018
-
2018Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States. Clinical and Applied Thrombosis/Hemostasis. 24:261S-268S.
-
2018Impact of Warfarin Persistence on Health-Care Utilization and Costs Among Patients With Atrial Fibrillation Managed in Anticoagulation Clinics in the United States. Clinical and Applied Thrombosis/Hemostasis. 24:364-371.
-
2017Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Current Medical Research and Opinion. 33:1745-1754.
-
2017Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY. 23:1191-1201.
-
2017Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. Thrombosis and Haemostasis. 117:1072-1082.
-
2017Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors. Journal of Medical Economics (JME). 20:1217-1223.
-
2017Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies. Current Medical Research and Opinion. 33:1583-1594.
-
2016An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Current Medical Research and Opinion. 32:573-582.
-
2016COMPARISON OF RIVAROXABAN OR WARFARIN USE FOR VENOUS THROMBOEMBOLISM ON INPATIENT LENGTH OF STAY. Journal of the American College of Cardiology. 67:2065-2065.
-
2016HOSPITAL READMISSIONS AMONG PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION TREATED WITH THE NEW ORAL ANTICOAGULANTS, APIXABAN, DABIGATRAN, AND RIVAROXABAN. Journal of the American College of Cardiology. 67:805-805.
-
2016Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options. Microbial Drug Resistance. 22:412-431.
-
2016Pulmonary Embolism Inpatients Treated With Rivaroxaban Had Shorter Hospital Stays and Lower Costs Compared With Warfarin. Clinical Therapeutics. 37:2496-2503.
-
2016Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions. Journal of the American Heart Association. 5.
-
2016Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation. Current Medical Research and Opinion. 32:87-94.
-
2015Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure. Current Medical Research and Opinion. 31:2167-2173.
-
2015Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for Warfarin Treatment With Apixaban or Aspirin Based on AVERROES Trial. Clinical and Applied Thrombosis/Hemostasis. 21:235-240.
-
2015Hospital length of stay for deep vein thrombosis or pulmonary embolism among patients receiving rivaroxaban or warfarin. Journal of Thrombosis and Haemostasis. 13:489-489.
-
2014Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. Journal of Thrombosis and Thrombolysis. 38:150-159.
-
2014Hospitalist Perspective on the Treatment of Skin and Soft Tissue Infections. Mayo Clinic Proceedings. 89:1436-1451.
-
2014Practical Considerations in the Use of Novel Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation. Cardiovascular Therapeutics. 32:74-81.
-
2014The Hospitalist Perspective on Treatment of Community-Acquired Bacterial Pneumonia. Postgraduate Medicine. 126:18-29.
-
2014The Key Principles and Characteristics of an Effective Hospital Medicine Group: An Assessment Guide for Hospitals and Hospitalists. Journal of Hospital Medicine. 9:123-128.
-
2013Bleeding as an Outcome Among Patients With Nonvalvular Atrial Fibrillation in a Large Managed Care Population. Clinical Therapeutics. 35:1536-1545.
-
2013Care Transitions in Anticoagulation Management for Patients With Atrial Fibrillation: An Emphasis on Safety. The Ochsner Journal. 13:419-427.
-
2013Hyponatremia-Associated Healthcare Burden Among US Patients Hospitalized for Cirrhosis. Advances in Therapy. 30:71-80.
-
2013Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks. Cardiology and Therapy. 2:165-170.
-
2013Warfarin Use and Stroke Risk Among Patients With Nonvalvular Atrial Fibrillation in a Large Managed Care Population. Clinical Therapeutics. 35:1201-1210.
-
2012COMPARISON OF TOTAL MEDICAL COST AVOIDANCE WITH THE USAGE OF NEW ORAL ANTICOAGULANTS INSTEAD OF WARFARIN AMONG ATRIAL FIBRILLATION PATIENTS, BASED ON THE ARISTOTLE, RE-LY AND ROCKET-AF TRIALS. Journal of the American College of Cardiology. 59:E599-E599.
-
2012Evaluation of incremental healthcare resource burden and readmission rates associated with hospitalized hyponatremic patients in the US. Journal of Hospital Medicine. 7:634-639.
-
2012Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records. Current Medical Research and Opinion. 28:1407-1414.
-
2011Consequences of Hyponatremia on Intensive Care Unit Cost and Length of Stay in Heart Failure Patients. Journal of Cardiac Failure. 17:S72-S72.
-
2011Impact of Hyponatremia on Inpatient Mortality and Hospital Readmission Rates in Hospitalized Patients with Heart Failure. Journal of Cardiac Failure. 17:S76-S76.
-
2011Prevalence of clinical venous thromboembolism in the USA: Current trends and future projections. American Journal of Hematology. 86:217-220.
-
2011Preventing Venous Thromboembolism Following Orthopedic Surgery in the United States: Impact of Special Populations on Clinical Outcomes. Clinical and Applied Thrombosis/Hemostasis. 17:640-650.
-
2011Prevention of venous thromboembolism in cancer patients: current approaches and opportunities for improvement. Oncology Reviews. 5:191-204.
-
2011Venous thromboembolism in the US: does race matter?. Journal of Thrombosis and Thrombolysis. 31:133-138.
-
2010Are surgical patients at risk of venous thromboembolism currently meeting the Surgical Care Improvement Project performance measure for appropriate and timely prophylaxis?. Journal of Thrombosis and Thrombolysis. 30:55-66.
-
2010Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Advances in Therapy. 27:623-633.
-
2010Thrombotic Risk and Immobility in Residents of Long-Term Care Facilities. Journal of the American Medical Directors Association. 11:211-221.
-
2009Assessing the Risk of Venous Thromboembolism and Identifying Barriers to Thromboprophylaxis in the Hospitalized Patient. Journal of Hospital Medicine. 4:S1-S7.
-
2009Improving Thromboprophylaxis: Performance Measures and Practical Strategies. Journal of Hospital Medicine. 4:S24-S30.
-
2009Optimizing Management of Venous Thromboembolism: Diagnosis, Treatment, and Secondary Prevention. Journal of Hospital Medicine. 4:S16-S23.
-
2009Optimizing the Prevention of Venous Thromboembolism: Recent Quality Initiatives and Strategies to Drive Improvement. Joint Commission Journal on Quality and Patient Safety. 35:558.
-
2009
-
2008Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism. Thrombosis and Haemostasis. 100:810-820.
-
2008Patterns and Predictors of Warfarin Use in Patients with Venous Thromboembolism. Blood. 112:1040-1040.
-
2008Peripheral arterial disease and the hospitalist: The rationale for early detection and optimal therapy. Journal of Hospital Medicine. 3:S4-S8.
-
2008VTE prevention in major orthopedic surgery - Reply. Cleveland Clinic Journal of Medicine. 75:472-473.
Visualizations
Research areas
- Business & Economics
- Cardiovascular System & Cardiology
- General & Internal Medicine
- Geriatrics & Gerontology
- Health Care Sciences & Services
- Hematology
- Infectious Diseases
- Microbiology
- Neurosciences & Neurology
- Oncology
- Pharmacology & Pharmacy
- Research & Experimental Medicine
- Science & Technology - Other Topics